Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload
Sponsor: Shire
Terminated
This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
Other terminated trials from Shire
Other Beta-Thalassemia trials with similar outcome
This PHASE2 trial investigates Beta-Thalassemia and Transfusional Iron Overload and is currently terminated or withdrawn. Shire leads this study, which shows 12 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
For direct contact, visit the study record on ClinicalTrials.gov .